Tue, Dec 23, 2014
A A A
Welcome Guest
Free Trial RSS
Get FREE trial access to our award winning publications
Industry Updates

Fitch: U.S. corporate bond downgrade rate 3% in second half 2009 vs 20% first half

Friday, February 19, 2010
Opalesque Industry Update - According to a new Fitch Ratings report, U.S. Corporate Bond Market: A Review of Fourth-Quarter and 2009 Ratings and Issuance Activity, the par value of U.S. corporate bonds affected by downgrades decreased for the third consecutive quarter in the last three months of 2009 to $42.9 billion or 1.2% of market volume, the lowest tally since the second quarter of 2007.

'With upgrades affecting $40.7 billion in bonds, the ratio of downgrades to upgrades was nearly even at year-end, a strong departure from rating activity in the first half of the year when downgrades towered over minimal upgrades' said Eric Rosenthal, Senior Director of Fitch Credit Market Research.

Downgrades continued to slow across the investment grade and speculative grade segments of the market at year-end.

The par downgrade rate (as a share of U.S. corporate bonds outstanding) was 23% in 2009, slightly below 2008's 24%. The vast majority, close to 90%, of the year's negative rating activity occurred in the first half of the year. For perspective, the par downgrade rate was 15.3% in 2001 and 23.4% in 2002.

The investment grade portion of the market experienced a downgrade rate of 20.1% in 2009 and the speculative grade segment, 34.7%. The share of bonds upgraded over the course of the year was 1.8% and 11.2%, respectively, across the two areas.

'The par downgrade rate associated with financial firms in 2009 was 36.5%, substantially higher than the downgrade rate of 12.7% recorded across industrials' said Mariarosa Verde, Managing Director of Fitch Credit Market Research.

Downgrades across financials had a particularly deep impact on the 'AAA' and 'AA' rating categories. At the end of the year, 'AAA' and 'AA' bonds had contracted to just 16.3% of market volume, down from 23.1% at the end of 2008 and 31.4% at the end of 2007.

The speculative grade portion of the market grew to 20.8% at the end of 2009, from 17.5% at the end of 2008 and 2007.

New issuance totaled $626.6 billion in 2009, up 3% year over year. Industrial issuance however grew 65% over the course of the year while financial issuance tumbled 55%.

The market's par rating composition at year-end consisted of the following: 'AAA', 0.7%; 'AA', 15.6%; 'A', 35.9%; 'BBB', 27.0%; 'BB', 8.2%; 'B', 6.8%; and 'CCC'-'C', 5.8%.-KM- To view full 20-page report, click Source

- KM -

What do you think?

   Use "anonymous" as my name    |   Alert me via email on new comments   |   
Today's Exclusives Today's Other Voices More Exclusives
Previous Opalesque Exclusives                                  
More Other Voices
Previous Other Voices                                               
Access Alternative Market Briefing


  • Top Forwarded
  • Top Tracked
  • Top Searched
  1. Hong Kong-Shanghai stock link fails to live up to expectation so far[more]

    Komfie Manalo, Opalesque Asia: In a report, Reuters said that demand has been subdued with the bulk of activities coming from short-term speculative investors. Las

  2. Investing - Hedge funds get boost from healthcare in 2014, Paulson & Co takes stake in Salix on heels of inventory issues[more]

    Hedge funds get boost from healthcare in 2014 From Valuewalk.com: The healthcare sector started the year on a turbulent note, as stocks of many major biotechnology companies were battered. However, most of the players in this sector have bounced back. The BarclayHedge Healthcare & Biotec

  3. North America - Why Steve Cohen, Connecticut hedge fund billionaire, gives so much in New York[more]

    From Insidephilantrophy.com: Billionaire Steve Cohen was born in Great Neck, New York before attending Wharton, working on Wall Street and then founding SAC Capital Advisors in Connecticut. Though his company (Point72) and foundation are based in Connecticut, Cohen and Alexandra are deeply connected

  4. Investing - Soros buys a highly speculative biotech in the third quarter[more]

    From Fool.com: …The Soros Fund bought 25,000 shares of the struggling small-cap biopharma Aegerion Pharmaceuticals in the third quarter. For those of you who haven't heard of this name, suffice to say that this was a surprising buy in light of the company's recent problems and poor outlook going for

  5. CFTC Revokes Registrations of Illinois Resident Aleks A. Kins and Chicago-based AlphaMetrix, LLC[more]

    Matthias Knab, Opalesque: The U.S. Commodity Futures Trading Commission (CFTC) today announced that it has revoked the registration of Aleks A. Kins of Chicago, Illinois, as an Associated Person and the registrations of AlphaMetrix, LLC (AlphaMetrix), a Delaware limited liability company with its